Video

Dr. Levy Discusses the FLAURA Study in Lung Cancer

Benjamin P. Levy, MD, assistant professor of oncology, clinical director of medical oncology, Johns Hopkins Sidney Kimmel Cancer Center, Johns Hopkins Medicine, discusses the FLAURA study in patients with lung cancer.

Benjamin P. Levy, MD, assistant professor of oncology, clinical director of medical oncology, Johns Hopkins Sidney Kimmel Cancer Center, Johns Hopkins Medicine, discusses the FLAURA study in patients with lung cancer.

FLAURA mirrored what was seen from the phase I frontline experience with osimertinib (Tagrisso). The progression-free survival (PFS) in the frontline setting ranged from 18 to 20 months, which was not seen before, explains Levy. This somewhat mirrors the alectinib (Alecensa) data in the ALK-positive patient population. It is practice changing when a PFS is close to 2 years, Levy says.

According to Levy, it is a different discussion when prescribing osimertinib to these patients because there is a low incidence of rash or diarrhea in trials of the agent. This had been practice changing, not only because of the PFS benefits, but also because there is lower toxicity and good data to suggest that osimertinib has a very good chance of crossing the blood-brain barrier and eliciting responses in the brain. This claim is based on data from the 2017 ASCO Annual Meeting. However, what to give a patient after osimertinib still requires more research, says Levy.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Jun 5th 2025 - Jul 12th 2025

online-activity